Investment Rating - The investment rating for Guobang Pharmaceutical is maintained at "Buy" [1] Core Views - The company is expected to achieve steady revenue growth in 2025, with projected revenue of 6.011 billion yuan, a year-on-year increase of 2.05%, and a net profit attributable to shareholders of 821 million yuan, up 5.02% [5] - The animal health segment is anticipated to reach a price turning point, leading to potential price increases in the future [5] - The company has adjusted its profit forecasts for 2026 and 2027, now estimating net profits of 1.060 billion yuan and 1.291 billion yuan respectively, with a new forecast for 2028 at 1.467 billion yuan [5] Financial Performance Summary - In 2025, the company achieved a revenue of 6.011 billion yuan, with a gross margin of 26.03% and a net margin of 13.6% [5] - The fourth quarter of 2025 saw a revenue of 1.542 billion yuan, but a decline in net profit to 151 million yuan, down 25.72% year-on-year [5] - The animal health segment's revenue grew by 15.35% to 2.492 billion yuan, while the pharmaceutical segment's revenue decreased by 9.08% to 3.475 billion yuan [6] Business Structure and Product Development - The company has optimized its business structure, with over 80 products in production and sales, including 13 products with sales exceeding 100 million yuan [6] - Significant growth in product shipment volumes was noted, with over 4,000 tons of Florfenicol and over 3,000 tons of Doxycycline shipped in 2025 [6] - The company has maintained a high level of research and development intensity, with a research expense ratio of 3.49% [7] Valuation Metrics - The current price-to-earnings (P/E) ratios for 2026, 2027, and 2028 are projected at 14.2, 11.6, and 10.2 respectively, indicating high valuation attractiveness [5] - The company’s return on equity (ROE) is expected to improve from 9.6% in 2025 to 12.3% by 2028 [9]

Investment Rating - The investment rating for Guobang Pharmaceutical is "Buy" (maintained) [1] Core Views - The company is expected to achieve steady revenue growth in 2025, with projected revenue of 6.011 billion yuan, a year-on-year increase of 2.05%. The net profit attributable to shareholders is forecasted to be 821 million yuan, up 5.02% year-on-year [5] - The animal health segment is anticipated to reach a price turning point, with a significant increase in sales volume for key products such as Florfenicol and Doxycycline [5][6] - The company has adjusted its profit forecasts for 2026-2027, now estimating net profits of 1.060 billion yuan and 1.291 billion yuan respectively, while introducing a new forecast for 2028 with a net profit of 1.467 billion yuan [5] Financial Performance - In 2025, the company achieved a gross margin of 26.03%, an increase of 1.03 percentage points, and a net margin of 13.6%, up 0.35 percentage points [5] - The revenue from the animal health segment was 2.492 billion yuan, reflecting a year-on-year growth of 15.35%, while the pharmaceutical segment saw a decline of 9.08% to 3.475 billion yuan [6] - The company has a high valuation attractiveness with a current price-to-earnings ratio (P/E) of 14.2 for 2026, 11.6 for 2027, and 10.2 for 2028 [5][9] Business Structure and Product Development - The company has optimized its business structure, with over 80 products in production and sales, including 13 products generating over 100 million yuan in revenue [6] - Significant progress in product registration has been made, with several key products receiving international certifications, enhancing the company's competitive position [7] Research and Development - The company maintains a high level of research and development intensity, with a research expense ratio of 3.49% in 2025 [7]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The animal health raw material drug prices are expected to experience a cyclical rebound in 2026 due to a recovery in industry demand and stabilization of antibiotic supply chain prices [1] - The heparin raw material drug industry is currently at a cyclical low, with prices declining sharply in 2023, but expected to stabilize by 2025 [2][56] - The vitamin industry is entering a price increase cycle influenced by geopolitical tensions and rising oil prices, leading to significant price increases for vitamin A and E [3][58] Summary by Sections Raw Material Prices and Trends - The PPI index for China's chemical raw materials has been on a downward trend, while upstream raw material prices are showing an upward trend, which may accelerate the supply clearance in the raw material drug industry [11][18] - Antibiotic prices, including 6-APA and penicillin industrial salt, are showing signs of recovery after hitting bottom [25][29] - The average price of florfenicol has dropped from 400-700 RMB/kg to 150-200 RMB/kg, indicating a significant decline due to oversupply and weak downstream demand [46][49] Investment Recommendations - The report suggests focusing on companies that have undergone thorough supply clearance and have expectations for price increases, recommending stocks such as Guobang Pharmaceutical, Puluo Pharmaceutical, and Aorite [4][72] - Beneficiary stocks include Meinuo Pharmaceutical, Chuaning Biological, and Zhejiang Pharmaceutical, among others [4][72] Price Trends in Specific Segments - Heparin API prices are expected to stabilize in 2025 after a period of decline due to oversupply [56][57] - Iodine raw material prices have seen a recovery due to strong demand from other industries, following a period of significant price increases [2][56] - The vitamin A and E prices are experiencing rapid increases due to geopolitical tensions affecting oil prices and supply chain disruptions [3][58]

Core Viewpoint - The company, a leader in AI-driven biomanufacturing, has achieved a valuation of 3.5 billion RMB and an annual production capacity exceeding 10,000 tons within ten years since its establishment in 2015 [1][3]. Company Overview - Founded in 2015 and headquartered in Suzhou, the company has established production bases in Hunan and Anhui, making it one of the few synthetic biology firms with a full chain capability from R&D to commercialization [3]. - The founder, Dr. Xie Xinkai, is a notable figure in synthetic biology, having studied under pioneers in the field and is credited with the first synthesis of simvastatin [3]. Financial Performance - The company reported a D-round post-investment valuation of 3.484 billion RMB, with its revenue structure primarily consisting of pharmaceutical intermediates, human nutrition, and animal nutrition [3]. - Revenue is projected to grow from 297.76 million RMB in 2023 to 344.59 million RMB in 2024, representing a 15.7% increase, and further to 379.99 million RMB in 2025, marking a 52.9% growth [7]. - The company has not yet achieved profitability, but losses are steadily narrowing, with net losses recorded at 146.55 million RMB for 2023 and 253.92 million RMB for 2024 [8]. Market Position - The company holds a significant market share in key products, ranking second globally in florfenicol (24.5%) and first in D-ethyl (44.5%), with its NMN product also holding a 11.4% market share [4]. - The primary product, florfenicol, is a veterinary antibiotic with a market size exceeding 3 billion RMB, while D-ethyl is a crucial intermediate for this drug [5]. Technological Advancements - The company has developed an enzyme-based synthesis process that addresses the inefficiencies of traditional multi-step chemical synthesis, leading to a more environmentally friendly and cost-effective production method [6]. - It has built a robust enzyme library containing over 10,000 enzymes and plans to integrate AI tools throughout its engineering workflow to enhance efficiency and automation [9][12]. Investment and Support - The company has a strong backing from prominent investors, including Yuexiu Capital, CICC Capital, and Hillhouse Capital, who recognize its technological advancements in biocatalysis [12].

Company Overview - The company, Yinhang Biotechnology, is a leader in synthetic biology driven by technological innovation, focusing on providing green, sustainable, and cost-effective bio-based products [2] - The company has established a strong market position, holding a 24.5% market share in the global florfenicol industry and a leading 44.5% market share in the D-ethyl market as of the nine months ending September 30, 2025 [2] Research and Development - Yinhang Biotechnology has developed a "dual-engine" R&D capability, which includes breakthrough original process design and efficient synthetic biology engineering supported by AI and high-throughput DBTL workflows [2][3] - The company has built two production bases for large-scale industrialization, which is crucial for rapid commercialization and achieving a leading market position [3] Financial Performance - The company reported revenues of approximately RMB 298 million for the fiscal year 2023, RMB 345 million for 2024, RMB 249 million for the nine months ending September 30, 2024, and RMB 380 million for the nine months ending September 30, 2025 [4] - Gross profit figures were approximately RMB 33.6 million for 2023, a loss of RMB 37.1 million for 2024, a loss of RMB 20.1 million for the nine months ending September 30, 2024, and a gross profit of RMB 5.6 million for the nine months ending September 30, 2025 [5][8] Market Trends - The global synthetic biology market is projected to grow from USD 21.5 billion in 2024 to USD 99.6 billion by 2030, with a compound annual growth rate (CAGR) of 23.2% from 2024 to 2035 [10] - The global market for raw materials and intermediates is expected to increase from USD 256.8 billion in 2024 to USD 347.7 billion by 2030, with a CAGR of 4.7% from 2024 to 2035 [12] - The D-ethyl market is anticipated to grow from USD 80.1 million in 2024 to USD 130.1 million by 2030, with a CAGR of 9.1% from 2024 to 2035 [15] - The global nutrition market is expected to rise from USD 170.9 billion in 2024 to USD 251.7 billion by 2030, with a CAGR of 6.0% from 2024 to 2035 [16]

Company Overview - The company, Yinhang Biotechnology, is a leader in synthetic biology driven by technological innovation, focusing on providing green, sustainable, and cost-effective bio-based products [2] - The company has established a leading market position in the production of active pharmaceutical ingredients (APIs) and intermediates, with a 24.5% market share in the global florfenicol industry and a 44.5% market share in the D-ethyl market as of the nine months ending September 30, 2025 [2] Research and Development - Yinhang Biotechnology has developed a "dual-engine" R&D capability, which includes breakthrough original process design and AI-assisted high-throughput DBTL workflows for efficient synthetic biology engineering [2][3] - The company has built two production bases for large-scale industrialization, which is crucial for rapid commercialization and achieving a leading market position [3] Financial Performance - The company reported revenues of approximately RMB 298 million for the fiscal year 2023, RMB 345 million for 2024, RMB 249 million for the nine months ending September 30, 2024, and RMB 380 million for the nine months ending September 30, 2025 [4] - The gross profit figures for the same periods were approximately RMB 33.6 million, -RMB 37.1 million, -RMB 20.1 million, and RMB 5.6 million respectively, indicating fluctuations in profitability [5][8] Market Trends - The global synthetic biology market is projected to grow from USD 21.5 billion in 2024 to USD 99.6 billion by 2030, with a compound annual growth rate (CAGR) of 23.2% from 2024 to 2035 [10] - The global market for APIs and intermediates is expected to increase from USD 256.8 billion in 2024 to USD 347.7 billion by 2030, with a CAGR of 4.7% from 2024 to 2035 [12] - The D-ethyl market is anticipated to grow from USD 80.1 million in 2024 to USD 130.1 million by 2030, with a CAGR of 9.1% from 2024 to 2035 [15]

Group 1 - The core viewpoint of the article is that Suzhou Leadsynbio Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as its sole sponsor [1] - The company is a leader in synthetic biology driven by technological innovation, focusing on providing green, sustainable, and cost-effective bio-based products [1] - The company has achieved a significant market position, holding a 24.5% market share in the global florfenicol industry, ranking second, and a 44.5% market share in the D-ethyl market, ranking first, based on revenue for the nine months ending September 30, 2025 [1]

Group 1 - The core viewpoint of the article is that Suzhou Leadsynbio Technology Co., Ltd. has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as its sole sponsor [1] - The company is positioned as a leader in synthetic biology driven by technological innovation, focusing on providing green, sustainable, and cost-effective bio-based products [1] - The company has achieved a significant market presence, holding a 24.5% market share in the global florfenicol industry, ranking second, and a 44.5% market share in the global D-ethyl market, ranking first, based on revenue for the nine months ending September 30, 2025 [1]

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不作任何陳述，並明確表示對因本申請版本的全部或任何部分內容而引致或因依賴本申請版本的全部或任何部 分內容而引致的任何損失不負任何責任。 Suzhou Leadsynbio Technology Co., Ltd. 蘇州引航生物科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）與證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即 代表 閣下知悉、接納並向本公司、其獨家保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例呈交香港公司註冊處處長註冊前， 本公司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約或邀請， 有意投資者務請僅依據呈交香港公司註冊處處長註冊的本公司招股章程作出投資決定；招股章 程的文本將於發售期內向公眾派發。 ...

Core Viewpoint - The report from Huachuang Securities indicates that while the industry is facing challenges due to increased competition, there is a stabilization and recovery in the prices of veterinary raw materials and vaccines, driven by innovation among successful companies [1] Vaccine Batch Release - In 2025, most vaccine varieties are expected to see year-on-year growth in batch releases, with new vaccines performing particularly well [1] - Specific growth rates for pig vaccines include: foot-and-mouth disease vaccine +6.4%, porcine circovirus vaccine +13.0%, pseudorabies vaccine +5.1%, swine fever vaccine +11.7%, and porcine enterovirus vaccine +21.3% [1] - For poultry vaccines, notable increases include avian influenza trivalent vaccine +22.8%, Newcastle disease vaccine +8.8%, and duck infectious serositis vaccine +17.3% [1] - The brucellosis vaccine for ruminants saw a significant increase of +61.6%, while the small ruminant plague vaccine decreased by -16.2% [1] - In the pet vaccine sector, domestic rabies vaccine and domestic cat trivalent vaccine increased by +22.1% and +32.3% respectively [1] Subspecies Analysis - In 2025, the economic product porcine circovirus vaccine and the mandatory immunization swine fever vaccine are expected to see faster growth due to increased farming profitability and pig output [2] - The rapid growth of the avian influenza trivalent vaccine and duck infectious serositis vaccine is attributed to heightened awareness of poultry diseases [2] - The brucellosis vaccine continues to maintain high growth rates due to the introduction of new products, while the small ruminant plague vaccine has seen a decline due to a high base from the previous year [2] Pet Vaccine Performance - The domestic cat trivalent vaccine, launched in early 2024, continues to show high growth in 2025 due to effective market promotion and consumer education [3] - Different types of vaccines for the same disease show varied performance, with the single foot-and-mouth disease vaccine decreasing by -0.7% and the multi-valent vaccine increasing by +8.9% [3] - The porcine foot-and-mouth disease OA bivalent vaccine saw a growth of +12.3%, while the porcine circovirus vaccine increased by +19.7% [3] Veterinary Raw Material Prices - In 2025, the Veterinary Product Index (VPI) is expected to rise by 7.2% year-on-year, with significant price increases in macrolide products [4] - Specific price increases include: tylosin +29.5%, tiamulin +11.4%, and tilmicosin +22.9% [4] - However, some products like florfenicol and amoxicillin have seen price declines of -5.9% and -21.0% respectively [4] - The market is anticipated to remain weak in the short term due to ongoing pressures in the farming sector and the traditional off-season for veterinary drugs [4]